Key Takeaways:
A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) on behalf of investors who purchased stock between March 26, 2025, and November 4, 2025.
The complaint, filed in the United States District Court for the Northern District of California, alleges that Soleno made materially false and misleading statements regarding its lead drug candidate, diazoxide choline extended-release (DCCR).
The lawsuit claims Soleno downplayed significant safety concerns in its Phase 3 clinical trial program, specifically related to excess fluid retention in patients. On November 4, 2025, after the company acknowledged disruptions to the drug's launch, Soleno's stock price fell more than 26 percent.
The legal filings put the commercial viability of DCCR—the company's treatment for hyperphagia, or excessive eating, in patients with Prader-Willi syndrome (PWS)—at risk. The company's November financial report noted a lower number of new patients starting the treatment and an increase in discontinuations following an August 15, 2025, report from Scorpion Capital that highlighted the clinical trial issues.
According to the lawsuit, Soleno Therapeutics and its executives failed to disclose that the administration of DCCR posed greater safety risks than the company had stated publicly. The complaint alleges this concealment gave a false impression of the drug's commercial prospects and its ability to gain widespread adoption among prescribers and patients.
The class action consolidates claims from investors who suffered financial losses and is being pursued by multiple law firms, including Faruqi & Faruqi, LLP, and Kessler Topaz Meltzer & Check, LLP.
Investors seeking to be appointed as a lead plaintiff in the case must file a motion with the court no later than May 5, 2026. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The ability to share in any potential recovery is not affected by the decision to serve as a lead plaintiff.
The decline puts the stock at its lowest since the November disclosure, testing recent support levels. The outcome of this class-action lawsuit, with the May 5, 2026, lead plaintiff deadline serving as a key date, is the next major catalyst for investors.
This article is for informational purposes only and does not constitute investment advice.
